Literature DB >> 29209939

Disaggregating the mortality reductions due to cancer screening: model-based estimates from population-based data.

James Anthony Hanley1, Sisse Helle Njor2,3.   

Abstract

The mortality impact in cancer screening trials and population programs is usually expressed as a single hazard ratio or percentage reduction. This measure ignores the number/spacing of rounds of screening, and the location in follow-up time of the averted deaths vis-a-vis the first and last screens. If screening works as intended, hazard ratios are a strong function of the two Lexis time-dimensions. We show how the number and timing of the rounds of screening can be included in a model that specifies what each round of screening accomplishes. We show how this model can be used to disaggregate the observed reductions (i.e., make them time-and screening-history specific), and to project the impact of other regimens. We use data on breast cancer screening to illustrate this model, which we had already described in technical terms in a statistical journal. Using the numbers of invitations different cohorts received, we fitted the model to the age- and follow-up-year-specific numbers of breast cancer deaths in Funen, Denmark. From November 1993 onwards, women aged 50-69 in Funen were invited to mammography screening every two years, while those in comparison regions were not. Under the proportional hazards model, the overall fitted hazard ratio was 0.82 (average reduction 18%). Using a (non-proportional-hazards) model that included the timing information, the fitted reductions ranged from 0 to 30%, being largest in those Lexis cells that had received the greatest number of invitations and where sufficient time had elapsed for the impacts to manifest. The reductions produced by cancer screening have been underestimated by inattention to their timing. By including the determinants of the hazard ratios in a regression-type model, the proposed approach provides a way to disaggregate the mortality reductions and project the reductions produced by other regimes/durations.

Entities:  

Keywords:  Birth-cohorts; Design matrix; Disaggregation; Lexis diagram; Screening, mortality, non-proportional hazards

Mesh:

Year:  2017        PMID: 29209939     DOI: 10.1007/s10654-017-0339-7

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  14 in total

1.  Analysis of mortality data from cancer screening studies: looking in the right window.

Authors:  James A Hanley
Journal:  Epidemiology       Date:  2005-11       Impact factor: 4.822

2.  Projecting the yearly mortality reductions due to a cancer screening programme.

Authors:  Zhihui Amy Liu; James A Hanley; Erin C Strumpf
Journal:  J Med Screen       Date:  2013-09-17       Impact factor: 2.136

3.  Measuring mortality reductions in cancer screening trials.

Authors:  James A Hanley
Journal:  Epidemiol Rev       Date:  2011-05-30       Impact factor: 6.222

4.  Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades.

Authors:  László Tabár; Bedrich Vitak; Tony Hsiu-Hsi Chen; Amy Ming-Fang Yen; Anders Cohen; Tibor Tot; Sherry Yueh-Hsia Chiu; Sam Li-Sheng Chen; Jean Ching-Yuan Fann; Johan Rosell; Helena Fohlin; Robert A Smith; Stephen W Duffy
Journal:  Radiology       Date:  2011-06-28       Impact factor: 11.105

5.  Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study.

Authors:  Anne Helene Olsen; Sisse H Njor; Ilse Vejborg; Walter Schwartz; Peter Dalgaard; Maj-Britt Jensen; Ulla Brix Tange; Mogens Blichert-Toft; Fritz Rank; Henning Mouridsen; Elsebeth Lynge
Journal:  BMJ       Date:  2005-01-13

6.  Decline in breast cancer mortality: how much is attributable to screening?

Authors:  Sisse Helle Njor; Walter Schwartz; Mogens Blichert-Toft; Elsebeth Lynge
Journal:  J Med Screen       Date:  2014-12-09       Impact factor: 2.136

7.  Long-term mortality after screening for colorectal cancer.

Authors:  Aasma Shaukat; Steven J Mongin; Mindy S Geisser; Frank A Lederle; John H Bond; Jack S Mandel; Timothy R Church
Journal:  N Engl J Med       Date:  2013-09-19       Impact factor: 91.245

8.  Early reporting for cancer screening trials.

Authors:  Stuart G Baker; Barnett S Kramer; Philip C Prorok
Journal:  J Med Screen       Date:  2008       Impact factor: 2.136

Review 9.  Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials.

Authors:  Mia Djulbegovic; Rebecca J Beyth; Molly M Neuberger; Taryn L Stoffs; Johannes Vieweg; Benjamin Djulbegovic; Philipp Dahm
Journal:  BMJ       Date:  2010-09-14

10.  Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study.

Authors:  S G Thompson; H A Ashton; L Gao; R A P Scott
Journal:  BMJ       Date:  2009-06-24
View more
  4 in total

1.  Inter- and intra-provincial variation in screen-detected breast cancer across five Canadian provinces: a CanIMPACT study.

Authors:  Marcy Winget; Yan Yuan; Mary L McBride; Cynthia Kendell; Kathleen M Decker; Eva Grunfeld; Patti A Groome
Journal:  Can J Public Health       Date:  2020-02-04

2.  Objectives, design and main findings until 2020 from the Rotterdam Study.

Authors:  M Arfan Ikram; Guy Brusselle; Mohsen Ghanbari; André Goedegebure; M Kamran Ikram; Maryam Kavousi; Brenda C T Kieboom; Caroline C W Klaver; Robert J de Knegt; Annemarie I Luik; Tamar E C Nijsten; Robin P Peeters; Frank J A van Rooij; Bruno H Stricker; André G Uitterlinden; Meike W Vernooij; Trudy Voortman
Journal:  Eur J Epidemiol       Date:  2020-05-04       Impact factor: 8.082

3.  UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis.

Authors:  Matthew Burnell; Aleksandra Gentry-Maharaj; Steven J Skates; Andy Ryan; Chloe Karpinskyj; Jatinderpal Kalsi; Sophia Apostolidou; Naveena Singh; Anne Dawnay; Robert Woolas; Lesley Fallowfield; Stuart Campbell; Alistair McGuire; Ian J Jacobs; Mahesh Parmar; Usha Menon
Journal:  Trials       Date:  2021-03-01       Impact factor: 2.279

Review 4.  Statistical analysis and decision making in cancer screening.

Authors:  Dik Habbema
Journal:  Eur J Epidemiol       Date:  2018-05-12       Impact factor: 8.082

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.